Elevance Health (ELV) Q1 2025 Earnings Transcript

Elevance Health reported Q1 adjusted diluted EPS of $11.97, up more than 10% year over year, on operating revenue of $48.8 billion, up over 15%, and reiterated full-year adjusted EPS guidance of $34.15-$34.85. Carelon operating gain rose 34% to $1.1 billion and the company repurchased 2.2 million shares for $880 million, but Medicaid cost pressure and a 86.4% benefit expense ratio remain headwinds. Management said Medicare Advantage retention was strong, Part D seasonality has shifted earnings earlier in the year, and operating cash flow guidance of about $8 billion is unchanged.

Analysis

The key read-through is not the headline EPS beat; it’s that Elevance is proving it can reprice around a more hostile utilization/regulatory backdrop without sacrificing growth. The mix shift toward ACA and disciplined MA enrollment is effectively a margin-protection strategy, while Carelon is becoming the earnings stabilizer that de-risks the health benefits book when Medicaid and Part D dynamics get noisy. That matters because it reduces the market’s ability to underwrite ELV on a simple managed-care multiple; the valuation floor should migrate toward a sum-of-the-parts framework where Carelon gets some services-like credit.

The second-order effect is on competitors with weaker services integration. If ELV is monetizing Carelon across internal and external clients while also pushing value-based care into MA, it forces peers to spend more on care management just to hold retention and medical cost trends steady. The near-term casualty is likely the more rate-sensitive Medicaid-heavy names and any MA operator that is more exposed to Part D seasonality whiplash without an internal pharmacy/services offset.

The risk is timing, not thesis: Medicaid recovery appears back-half weighted, while ACA membership moderation and Part D seasonality front-load reported strength. That sets up a possible “good Q1, noisy Q2” setup where investors overreact to a temporary lull in membership or cash flow before the rate cycle and working-capital reversals show through. The real downside catalyst would be if July Medicaid renewals disappoint or if utilization in MA stops being merely elevated and turns into a structurally higher new normal, which would pressure 2026 bid behavior before the market can fully reprice it.

Contrarian view: consensus is still treating ELV like a defensive insurer with manageable trend, but the more interesting angle is that it’s increasingly a healthcare platform with embedded distribution and care-management leverage. If Carelon external growth sustains above 50% and specialty/pharmacy migration continues, the market is underestimating the earnings durability of the non-underwriting businesses. In that scenario, the stock may be less about near-term MLR noise and more about an underestimated re-rating of the services contribution over the next 6-12 months.

Key Decisions for Investors

• Go long ELV on any post-Q1/early-Q2 weakness; use a 3-6 month horizon with a risk/reward skew favoring a re-rating toward a higher services multiple as Medicaid rate visibility improves.
• Pair trade: long ELV / short UNH or short HUM on a 1-2 quarter view to express relative resilience in rate negotiation, Carelon monetization, and better earnings smoothing from Part D mix.
• Buy ELV Jan-2026 call spreads to capture a 6-12 month re-rating while capping premium risk; thesis works if Carelon remains a >50% growth engine and Medicaid improves in H2.
• Avoid chasing pure MA or Medicaid-heavy peers until July rate outcomes are clearer; ELV looks like the cleaner way to own managed care with less binary downside.
• If ELV rallies sharply into the next print, consider monetizing upside via covered calls rather than outright trimming, since the more important catalyst is likely H2 rate realization rather than Q2 headline volatility.